In vivo selection of genetically modified bone marrow cells

Progress in Experimental Tumor Research

Volumn 36, Issue , 1999, Pages 162-171

  Blau, C Anthony ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW CELL; CELL SEPARATION; CYTOLOGY; GENE TRANSFER; HUMAN; METHODOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

BONE MARROW CELLS; CELL SEPARATION; GENE TRANSFER TECHNIQUES; HUMANS; SIGNAL TRANSDUCTION;

EID: 0032612342     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (37)

1. Brenner MK: Gene transfer into hematopoietic cells. N Engl J Med 1996;335:337-339.
2. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134-1137.
3. Dunbar CE, Cottier-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS, Nienhuis AW: Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048-3057.
4. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257:99-103.
5. Aran JM, Gottesman MM, Pastan I: Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA 1994;91:3176-3180.
6. Migita M, Medin JA, Pawliuk R, Jacobson S, Nagle JW, Anderson S, Amiri M, Humphries RK, Karlsson S: Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci USA 1995;92:12075-12079.
7. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ: Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 1996;87:30-37.
8. Simonsen CC, Levinson AD: Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 1983;80:2495-2499.
9. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
10. Allay JA, Davis BM, Gerson SL: Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp Hematol 1997;25:1069-1076.
11. NeffT, Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996;24:1340-1346.
12. Momparler RL, Laliberté J, Eliopoulos N, Beauséjour C, Cournoyer D: Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. Anticancer Drugs 1996;7:266-274.
13. Blau CA, Neff T, Papayannopoulou Th: The hematological effects of folate analogs: Implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Ther 1996;7:2069-2078.
14. Blau CA, Neff T, Papayannopoulou Th: Cytokine prestimulation as a gene therapy strategy: Implications for using the MDR1 gene as a dominant selectable marker. Blood 1997;89:146-154.
15. Stromhaug A, Warren DJ, Slordal L: Effect of methotrexate on murine bone marrow cells in vitro: Evidence of a reversible antiproliferative action. Exp Hematol 1995;23:439-443.
16. Stromhaug A, Slordal L, Warren DJ: Differential effects of the antifolates methotrexate, aminopterin and trimetrexate on murine haemopoietic progenitor cells. Br J Hematol 1996;92:514-520.
17. Stead RB, Kwok WW, Storb R, Miller AD: Canine model for gene therapy: Inefficient gene expression in dogs reconstituted with autologous marrow infected with retroviral vectors. Blood 1988;71: 742-747.
18. Corey CA, DeSilva AD, Holland CA, Williams DA: Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 1990;75:337-343.
19. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89:9676-9680.
20. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257:99-103.
21. Fleming WH, Alpern EJ, Uchida N, Ikuta K, Weissman IL: Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells. J Cell Biol 1993;122:897-902.
22. Molineux G, Migdalska A, Haley J, Evans GS, Dexter TM: Total marrow failure induced by pegylated stem-cell factor administration before 5-fluorouracil. 1994;83:3491-3499.
23. Harrison DE, Zsebo DM, Astle CM: Splenic primitive hematopoietic stem cell (PHSC) activity is enhanced by steel factor because of PHSC proliferation. Blood 1994;83:3146-3151.
24. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP: Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 1997; 90:3546-3554.
25. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR: Controlling signal transduction with synthetic ligands. Science 1993;262:1019-1034.
26. Spencer DM, Belshaw PJ, Chen L, Ho SN, Randazzo F, Crabtree GR, Schreiber S: Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol 1996;6:839-847.
27. Rivera V, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F, Holt DA, Oilman M: A humanized system for pharmacologie control of gene expression. Nat Med 1996;2:1028-1032.
28. Palacios R, Steinmetz M: IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985;41:727-734.
29. Li JP, D'Andrea AD, Lodish HF, Baltimore D: Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 1990;343:762-764.
30. Blau CA, Peterson KR, Drachman JG, Spencer DM: A proliferation switch for genetically modified cells. Proc Natl Acad Sci USA 1997;94:3076-3081.
31. Jin L, Asano H, Blau CA: Stimulating cell proliferation through the pharmacologie activation of c-kit. Blood 1998;91:890-897.
32. Jin L, Siritanaraktul N, Emery DW, Richard RE, Kaushansky K, Papayannopoulou Th, Blau CA: Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci USA, in press.
33. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CD, Oort PJ, Grant FJ, Hepel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg J, Johnson R, Pronkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SO, Evans SJ, Sheppard PO, Presnell SR, O'Hara PJ, Hagen FS, Roth GJ, Foster DC: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
34. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hage RS, Roth GJ, Papayannopoulou T, Foster DC: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
35. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W: c-mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-574.
36. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC: Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996;24:265-269.
37. Hawley RG, Lieu FHL, Fong AZC, Hawley TS: Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994;1:136-138.